Here’s a pattern we see repeatedly in the RWE programmes we advise on across Continental European markets: a company selects a longitudinal dataset based on vendor reputation, a familiar commercial relationship, or headline coverage numbers — and then builds a study design around what the data can actually deliver. The requirements get retrofitted to the dataset, rather than the dataset being selected against pre-specified requirements. And six months later, the study is either underpowered, the follow-up period is demonstrably insufficient for the outcomes being measured, or a regulatory reviewer is asking questions about index date methodology that nobody documented a clear answer to at the time.
This sequence is entirely predictable. It’s also entirely preventable — but only if you define what a fit-for-purpose longitudinal dataset looks like for your specific study before you start talking to vendors. That distinction — requirements first, data source selection second — is the single most important structural difference between RWE programmes that generate credible, regulatory-grade evidence and those that don’t.
This post covers the four methodological components that determine whether a longitudinal dataset is actually fit for your purpose: minimum follow-up duration requirements, index date definition, attrition and censoring management, and what “longitudinal depth” actually means when a vendor uses the term. It closes with a practical framework for translating those requirements into vendor conversations that produce accurate responses rather than optimistic sales claims.
It builds on the foundational data source taxonomy covered in the RWD Medical pillar page — if you’re new to the landscape of real-world data source types that support longitudinal analysis, that’s the right starting point before this one.
Why Most RWE Studies Encounter Design Failures Before Analysis Begins
Let me be direct about something the industry doesn’t talk about clearly enough: the majority of RWE study failures are not statistical failures. They’re design failures. And they happen before the first patient record is analysed.
The mechanism is consistent. FDA guidance — and increasingly EMA guidance through the DARWIN EU framework — is explicit that real-world data sources should be evaluated for relevance and reliability after study requirements and outcomes are finalised. Not before. The methodological logic is straightforward: if you define your data requirements based on what a vendor has available, you’ve allowed the data infrastructure to determine your research question rather than the other way around. That’s a fundamental inversion of scientific rigour.
But in practice, this inversion is the norm. Companies have existing vendor relationships, familiar datasets, procurement processes that favour known suppliers. Study designs get quietly adjusted to fit the follow-up period the preferred dataset actually has, rather than the follow-up period the outcomes under investigation actually require. The adjustment is rarely documented explicitly — it just happens, incrementally, in design meetings where dataset constraints are treated as fixed and study requirements as negotiable.
The consequences are predictable and expensive. Studies locked into datasets that can’t support their analytical objectives require redesign or complete restart. Regulatory submissions built on datasets with insufficient follow-up, poorly documented index date methodology, or uncharacterised attrition patterns face the kind of scrutiny that delays approvals and, in the cases that generate public consequences, produces the regulatory and financial outcomes that make the risk concrete rather than theoretical.
The discipline required is simple to state and genuinely difficult to enforce organisationally: specify your longitudinal requirements completely before you enter any vendor conversation. The rest of this post gives you the framework for doing that.
Minimum Follow-Up Duration: Calculating What Your Study Actually Needs
Minimum follow-up duration is not a number you get from a vendor. It’s a number you calculate from your study design — and then use to evaluate what vendors can deliver. Getting that sequence right is, again, the fundamental principle.
Start with outcome-specific observation periods
The minimum observation period calculation starts with the clinical characteristics of the outcomes you’re measuring. For safety outcomes, the biological onset timeframe for adverse events of interest drives the calculation — some adverse events manifest within weeks of exposure, others require years of follow-up to detect reliably. For effectiveness outcomes, the expected time to clinical response and the duration needed to establish sustained benefit or lack thereof defines the floor.
Chronic disease studies present particular complexity. Meaningful effectiveness endpoints may require twelve to twenty-four months of follow-up, while safety signals for the same intervention may emerge within weeks. The study design needs to accommodate the longest clinically relevant timeframe while ensuring sufficient patient retention to maintain statistical power throughout that window. These two requirements — adequate duration and adequate retention — are often in tension, and resolving that tension requires explicit design decisions rather than implicit assumptions about what the data will support.
Many adverse drug reactions and longer-term health consequences manifest years or decades after initial exposure. Pan-European health insurance claims databases and registry-linked datasets can enable patient follow-up of ten years or longer — but the availability of that temporal depth in a vendor’s headline coverage statistics doesn’t tell you whether the data is complete, consistently coded, and analytically reliable across that full period. That distinction is what “longitudinal depth” actually means, and we’ll come back to it in detail.
Account for outcome detection windows
Outcome detection windows are the period during which events can be reliably captured and attributed to the exposure under study. In claims data, this window is bounded by what generates a billing event — outcomes that don’t result in healthcare utilisation won’t appear at all, regardless of how long the follow-up period is. In EHR-linked datasets, the detection window depends on whether the relevant care episodes are captured within the linked system or occur outside it.
Diagnostic delay patterns matter too. Some conditions have lengthy diagnostic workups — the actual outcome occurs weeks or months before the diagnostic code appears in the claims record. This temporal lag affects both the minimum follow-up calculation and the interpretation of results. An algorithm that uses first recorded diagnosis code as the outcome date without accounting for diagnostic lag will systematically mistime events in ways that bias time-to-event analyses. This is, incidentally, a direct connection to the phenotype algorithm design challenges covered in our post on phenotype validation in claims data — the two methodological problems compound each other when both are present in the same study.
Build in margins for data latency
Data latency — the time between real-world events and their availability in analytical datasets — is systematically underestimated in follow-up duration planning. Claims data typically carries several months of lag between healthcare events and analytical availability. EHR data has shorter but more variable delays. The practical implication: a study requiring twelve months of effective follow-up may need to specify eighteen months of theoretical coverage to ensure complete outcome capture, particularly for studies involving rare events or complex diagnostic procedures.
Latency assessment needs to be granular rather than average. Laboratory results, diagnosis codes, and prescription records often have different latency profiles within the same dataset. A vendor who quotes an overall data latency figure without distinguishing between data element types is giving you information that’s too coarse to be analytically useful.
Index Date Definition: The Design Decision That Shapes Everything Downstream
If minimum follow-up duration is the most commonly underspecified requirement, index date definition is the most consequential design decision that gets made without adequate documentation. The index date is the reference point from which all longitudinal measurements flow — exposure windows, follow-up periods, outcome timing, covariate assessment windows. Get it wrong, or define it vaguely, and every downstream analysis inherits the error.
Simulation studies have demonstrated that different time-zero settings — different definitions of the index date — can produce contradictory conclusions even when the same dataset is analysed for identical research questions. The same patient population, the same outcome, the same analytical approach, but different index date definitions producing different results. This isn’t a minor sensitivity. It’s the difference between a study that supports regulatory approval and one that doesn’t.
Clean window requirements
Clean windows establish the period before the index date during which specified events or exposures must not occur. The purpose is to ensure that index events represent genuinely new episodes rather than continuation or recurrence of prior conditions. For chronic conditions, clean window requirements typically range from six to twelve months — meaning the first year of available data in a longitudinal dataset cannot contribute index events, which directly affects how much of the dataset’s temporal coverage is analytically usable.
This is one of the places where vendor coverage claims and analytical reality diverge most reliably. A dataset described as having five years of longitudinal coverage may have only four years of usable follow-up once clean window requirements are applied — and less than that once data latency margins are added. Specifying clean window requirements before vendor conversations ensures you’re evaluating actual analytical coverage rather than headline temporal depth.
Reference point selection
For prescription-based studies, the choice between prescription date, dispensing date, and first administration can meaningfully affect study results — particularly for outcomes with narrow risk windows where exposure timing precision matters. Each reference point carries different assumptions about patient behaviour and healthcare system processes. Dispensing date is the most commonly available reference point in claims data, but it doesn’t correspond to actual first administration in patients who fill prescriptions without immediately taking them.
For studies with multiple potential index event types — first prescription of any drug in a class, first prescription meeting specific dosing criteria, first specialist consultation — the reference point selection becomes more complex, and the choices need to be made explicitly and documented before the analytical phase begins. Post-hoc index date adjustments are a consistent source of regulatory challenge because they raise the question of whether the methodology was selected to fit the data rather than the data selected to fit the methodology.
Attrition and Censoring: Anticipating the Patterns That Undermine Longitudinal Validity
Attrition — patients dropping out of observation before the study’s minimum follow-up period is complete — is an expected feature of longitudinal studies, not an unexpected problem. The question isn’t whether attrition will occur; it’s whether it’s random or systematic, and whether the analytical approach accounts for its actual pattern.
Systematic attrition is analytically dangerous in ways that random attrition isn’t. Research consistently identifies predictable risk factors for dropout across longitudinal healthcare datasets: patients with lower socioeconomic status, poorer baseline health, and specific comorbidities including cardiovascular disease demonstrate higher dropout rates. In Continental European statutory health insurance data, administrative censoring — patients moving between insurance systems, changing coverage, or relocating across national boundaries — adds a layer of systematic attrition that isn’t clinically meaningful but can introduce confounding if not addressed.
The implication for study design is that attrition patterns need to be anticipated before data access rather than characterised after. For a Pan-European study drawing on health insurance claims data across multiple national markets, the attrition patterns in each market reflect both clinical characteristics and administrative infrastructure — and they’re different enough across markets that a single attrition handling approach applied uniformly will be inadequate for at least some of them.
Statistical approaches for non-random missing data
Missing data in longitudinal studies rarely occurs completely at random, which means analytical approaches that assume randomness — complete case analysis, for example — produce biased estimates in a direction that’s difficult to predict without explicitly modelling the missingness mechanism. Multiple imputation methods can address some missing data challenges, but they require careful specification: the imputation model needs to reflect the actual data generation process, and sensitivity analyses need to explore how different missing data assumptions affect primary conclusions.
Inappropriate censoring — treating administrative data gaps as study endpoints, for example — can substantially bias median survival estimates in time-to-event analyses. This is one of the most common causes of RWE submission rejection by both FDA and EMA reviewers, and it’s directly preventable through upfront specification of censoring rules that distinguish between true study endpoints, administrative data gaps, and patient dropout. Specifying those rules before data access means they can be evaluated against the dataset’s actual administrative structure — rather than discovered to be inadequate after the analysis is complete.
Longitudinal Depth: What the Term Actually Means and How to Evaluate It
Vendors use “longitudinal depth” to describe almost everything — years of coverage, patient volume, data element richness, coding completeness. When a term can mean everything, it effectively means nothing, and evaluating vendor claims about longitudinal depth without a defined specification framework produces exactly the kind of mismatch between expectation and delivery that drives RWE study failures.
Longitudinal depth, defined rigorously, means the extent to which a dataset enables complete, consistent, analytically reliable observation of patient journeys across the full study period. That definition breaks into three components that need to be assessed independently:
Temporal coverage and data continuity
Temporal coverage is the headline number — how many years of data are available. Data continuity is the analytically relevant question — whether that coverage is consistent and complete across the full period, or whether it includes gaps, changes in coding methodology, shifts in the underlying patient population due to changes in the insurance system, or variations in data capture completeness across years. A dataset with ten years of nominal coverage but inconsistent coding practices in the first three years has substantially less usable longitudinal depth than the headline figure suggests.
Patient journey completeness
Journey completeness requires assessment across multiple dimensions: care setting representation, clinical event capture, and prescription fill completeness relative to prescribing patterns. A claims dataset may have strong primary care and hospital coverage but systematically miss specialist consultations billed outside the statutory insurance system — which in many Continental European markets is a meaningful gap for conditions managed primarily by specialists. Emergency department visits, out-of-network care, and care delivered in settings with different administrative coding conventions all represent potential completeness gaps that headline coverage statistics don’t reveal.
Submission-ready data quality standards
The FDA’s adoption of ICH M14 establishes explicit standards for designing, analysing, and reporting non-interventional pharmacoepidemiological studies, with specific requirements for pre-specified study design, data provenance documentation, and statistical approach justification. EMA’s DARWIN EU framework is establishing parallel standards for European submissions. Submission-ready data quality exceeds the quality thresholds used in routine commercial analytics — it requires additional validation, documented quality assessments, and handling of data uncertainties that most vendors don’t treat as standard deliverables unless explicitly specified.
Asking a vendor for their data quality documentation — not their marketing materials, their actual validation methodology and quality assessment reports — is the most reliable indicator of whether their dataset will support regulatory-grade use. The vendor evaluation framework we’ve developed for navigating these conversations covers the specific questions to ask and what credible responses look like.
Translating Requirements into Vendor Conversations That Produce Accurate Responses
The practical challenge is that even well-specified requirements don’t automatically produce accurate vendor responses. Vendor sales teams are optimised to find a positive answer to almost any requirements question — which means vague questions produce optimistic answers that don’t survive contact with the actual dataset. Precise, operationalised requirements produce responses that are either clearly adequate or clearly inadequate, which is the information you actually need.
Pre-specify study design parameters in operational terms
Study design parameters need to be specified at the level of operational detail that leaves no room for vendor interpretation. “Cardiovascular outcomes” needs to become specific ICD-10 code sets, diagnostic criteria, acceptable capture mechanisms, and minimum event frequency thresholds. “Adequate follow-up” needs to become a minimum number of months of continuous observation per patient, with explicit criteria for what constitutes a gap that breaks continuity.
Edge case specifications matter as much as primary criteria. How should the study handle patients who switch insurance plans during follow-up? What constitutes adequate exposure data for time-varying treatments? What is the acceptable threshold for missing covariate data before a patient is excluded from the analytical cohort? These details significantly affect both dataset selection and analytical approach — and they’re the details most likely to produce mismatch between what you contracted for and what you received if left unspecified.
Document data provenance requirements explicitly
Data provenance documentation — the traceability of data elements back to their original sources, the handling of data quality issues, and the documentation of any transformations applied during dataset construction — is a regulatory requirement for submissions and a practical necessity for any study that may face external scrutiny. Most vendors focus primarily on delivering cleaned, analysis-ready datasets. Documentation of how that cleaning was done, what assumptions were made, and what quality checks were applied often requires explicit contractual specification rather than being assumed as a standard deliverable.
This connects directly to the analytical quality considerations covered in our post on analysis-ready real-world evidence and healthcare data — what “analysis-ready” means in practice, and what documentation should accompany a dataset that claims that standard.
Establish analytical approach requirements before procurement
Analytical approach requirements — the statistical methods planned for the study, the required data granularity to support those methods, and any specific formatting or structural needs — determine data requirements that aren’t visible from the study design alone. Time-to-event analyses require different data structures than cross-sectional comparisons. Marginal structural models for time-varying confounding require time-updated covariate data at a granularity that not all longitudinal datasets provide. Specifying these requirements before procurement, rather than discovering their implications after data access, is the difference between a smooth analytical phase and one that requires expensive data restructuring or analytical compromises.
The Advisory Perspective: Where the Specification Gap Creates the Most Risk
In the longitudinal RWE programmes we advise on, the specification gap — the distance between what a company intended to study and what the contracted dataset actually supports — is most commonly created at two moments: during the internal study design phase, when follow-up requirements get quietly adjusted to fit a preferred dataset without that adjustment being documented; and during vendor negotiations, when vague requirements meet optimistic vendor responses and nobody asks the follow-up questions that would reveal the mismatch.
Both moments are preventable. The internal design phase requires organisational discipline to hold study requirements fixed and treat data source selection as a downstream decision. The vendor negotiation phase requires the kind of operationalised specification framework described above — precise enough that vendor responses are either clearly adequate or clearly inadequate, rather than technically accurate but practically misleading.
What makes this genuinely difficult is that the people who understand the methodological requirements deeply enough to write precise specifications are often not the same people who manage vendor relationships and procurement processes. Bridging that gap — between methodological rigour and operational execution — is where external advisory support adds the most consistent value in longitudinal RWE programmes.
If you’re scoping a longitudinal RWE study and want an independent assessment of your dataset requirements before entering vendor conversations, contact us to discuss your specific evidence requirements. Getting the specification right before procurement begins is the highest-leverage point in the entire study lifecycle — and it’s where early advisory input prevents the most expensive problems.
If you want to apply this framework immediately, the MEDDDICAL guide on longitudinal data requirements — available at longitudinaldata.medddical.com — provides the concrete specification language you can take directly into vendor conversations. And if you’re scoping a longitudinal RWE study and want an independent assessment of your dataset requirements before engaging vendors, contact us to discuss your specific evidence requirements
Sources & References
- U.S. Food and Drug Administration (2021). Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products. https://www.fda.gov
- U.S. Food and Drug Administration (2024). Real-world data: assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products. https://www.fda.gov
- European Medicines Agency (2023). Data analysis and real-world interrogation network (DARWIN EU). https://www.ema.europa.eu
- Hernán, M. A., & Robins, J. M. (2016). Using big data to emulate a target trial when a randomized trial is not available. American Journal of Epidemiology, 183(8), 758–764. https://academic.oup.com/aje
- Schneeweiss, S., et al. (2019). Graphical depiction of longitudinal study designs in health care databases. Annals of Internal Medicine, 170(6), 398–406. https://www.acpjournals.org
- Sterne, J. A. C., et al. (2009). Multiple imputation for missing data in epidemiological and clinical research. BMJ, 338, b2393. https://www.bmj.com
- Benchimol, E. I., et al. (2015). The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLOS Medicine, 12(10). https://journals.plos.org/plosmedicine
- ISPOR-ISPE Special Task Force. Good practices for real-world data studies of treatment and/or comparative effectiveness. https://www.ispor.org
- ICH M14 Guideline. General principles on plan, design and analysis of pharmacoepidemiological studies that use real-world data for safety assessment of medicines. https://www.ich.org
- Hernán, M. A., Sauer, B. C., Hernández-Díaz, S., Platt, R., & Shrier, I. (2016). Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. Journal of Clinical Epidemiology, 79, 70–75. https://www.jclinicalepidemiologyjournal.com
